Payment overview · 2025
General Payments
$1,677.90
67 reported records · 18 companies
Healthcare provider profile · identity verified
Malik S Ali, MD
Allopathic & Osteopathic Physicians|General Practice · MILWAUKEE, WI · NPI 1124037437
Verified facts
What the public records show
CMS Open Payments records show Malik S Ali, MD received $1,677.90 in general payments during 2025 across 67 reported records.
ABBVIE INC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Invega Sustenna, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 495 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 495 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $301.51 | 18.0% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $249.85 | 14.9% | 10 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $196.68 | 11.7% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $140.10 | 8.3% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $123.26 | 7.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.23 | 5.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.35 | 5.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.64 | 4.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.61 | 4.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.42 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $57.71 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.94 | 2.6% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.05 | 2.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.04 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.79 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.88 | 1.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.69 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.15 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,677.90 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $197.81 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $155.67 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.74 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $123.26 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $121.50 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.35 | 4 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $80.64 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $80.61 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.88 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $63.55 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $41.05 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $38.05 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 495 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
142 | 29 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
495 | 51 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
110 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
495 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 809 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 546 | 118 |
| Eliquis | Apixaban | 495 | 51 |
| Gabapentin | Gabapentin | 430 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 75 |
| Losartan Potassium | Losartan Potassium | 321 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 299 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 47 |
| Furosemide | Furosemide | 257 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 40 |
| Carvedilol | Carvedilol | 215 | 44 |
| Levetiracetam | Levetiracetam | 212 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 204 | 38 |
| Sertraline Hcl | Sertraline Hcl | 198 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 196 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 37 |
| Atropine Sulfate | Atropine Sulfate | 191 | suppressed |
| Baclofen | Baclofen | 184 | 36 |
| Metformin Hcl | Metformin Hcl | 180 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 33 |
| Lisinopril | Lisinopril | 176 | 40 |
| Mirtazapine | Mirtazapine | 167 | 31 |
| Potassium Chloride | Potassium Chloride | 165 | 44 |
| Trazodone Hcl | Trazodone Hcl | 162 | 40 |
| Promethazine Hcl | Promethazine Hcl | 157 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 39 |
| Linzess | Linaclotide | 142 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 42 |
| Omeprazole | Omeprazole | 136 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 132 | 17 |
| Januvia | Sitagliptin Phosphate | 124 | 11 |
| Divalproex Sodium | Divalproex Sodium | 123 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 120 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 118 | 22 |
| Alendronate Sodium | Alendronate Sodium | 111 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 26 |
| Buspirone Hcl | Buspirone Hcl | 110 | 22 |
| Xarelto | Rivaroxaban | 110 | suppressed |
| Allopurinol | Allopurinol | 109 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 24 |
| Montelukast Sodium | Montelukast Sodium | 106 | 19 |
| Scopolamine | Scopolamine | 106 | 16 |
| Simvastatin | Simvastatin | 105 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 33 |
| Midodrine Hcl | Midodrine Hcl | 103 | 21 |
| Ibuprofen | Ibuprofen | 97 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 30 |
| Finasteride | Finasteride | 88 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 88 | 17 |
| Famotidine | Famotidine | 83 | 24 |
| Metoclopramide Hcl | Metoclopramide Hcl | 82 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 11 |
| Latanoprost | Latanoprost | 68 | 16 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 68 | suppressed |
| Pregabalin | Pregabalin | 61 | suppressed |
| Spironolactone | Spironolactone | 61 | 18 |
| Prednisone | Prednisone | 59 | 24 |
| Tramadol Hcl | Tramadol Hcl | 59 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 15 |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Lorazepam | Lorazepam | 57 | 23 |
| Risperidone | Risperidone | 57 | suppressed |
| Alprazolam | Alprazolam | 56 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 55 | 20 |
| Meloxicam | Meloxicam | 55 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 13 |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Fluconazole | Fluconazole | 47 | 18 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 46 | 34 |
| Ketoconazole | Ketoconazole | 45 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Lacosamide | Lacosamide | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 22 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Lubiprostone | Lubiprostone | 37 | suppressed |
| Brilinta | Ticagrelor | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 31 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 31 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 18 |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Acetic Acid | Acetic Acid | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 21 |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 12 |
| Metronidazole | Metronidazole | 23 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 12 |
| Budesonide | Budesonide | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | 15 |
| Nystatin | Nystatin | 19 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 11 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,677.90 · 67 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, CAPVAXIVE, CREON, ELIQUIS, ETERNA, FARXIGA, GARDASIL 9, INVEGA SUSTENNA, Kerendia, LINZESS, MAVYRET, NUZYRA, Ozempic, QULIPTA, REXULTI, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, VYNDAMAX, Veozah, Wegovy, XHANCE, ZENPEP | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error